Pharmac funds immunotherapy drug Durvalumab for Lung Cancer
Pharmac is now funding a new immunotherapy medicine called durvalumab (Imfinzi) which could be life-changing for the 300 patients diagnosed with Stage 3 non-small cell lung cancer every year in New Zealand. Durvalumab is the first immunotherapy drug to be funded for lung cancer in New Zealand and it has the potential to control cancer beyond the point of detection.
CEO of Lung Foundation New Zealand, Philip Hope, acknowledged Pharmac and AstraZeneca for negotiating reimbursement of durvalumab, which is the standard of care for this type of lung cancer – mindful of the 1500 patients diagnosed with Stage 4 lung cancer who do not yet have access to the standard of care in New Zealand.
Click to view the full report –